Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Berger

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Radiation Research|December 4, 2003
Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrastLois B Travis, Michael Hauptmann, Linda Knudson Gaul, et al.
Plos One|July 7, 2015
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational StudyEmmanuelle Leray, Sandra Vukusic, Marc Debouverie, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2020
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MSMikael Cohen, Lydiane Mondot, Florence Bucciarelli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2024
Association between education level and disability progression in patients with multiple sclerosis in FranceMathilde Lefort, Olivier Dejardin, Eric Berger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in FranceMathilde Lefort, Olivier Dejardin, Eric Berger, et al.
Annals of Clinical and Translational Neurology|August 8, 2025
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple SclerosisAlexandra Garcia, Stephane Rodriguez, Emilie Dugast, et al.
Annals of Clinical and Translational Neurology|April 8, 2021
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament-light chain in multiple sclerosisAudrey Gauthier, Sébastien Viel, Magali Perret, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 22, 2023
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple SclerosisAlexandra Garcia, Emilie Dugast, Sita Shah, et al.
Neurology|October 12, 2023
Comparison of 2 Methods for Estimating Multiple Sclerosis-Related MortalityFabien Rollot, Zoé Uhry, Emmanuelle Dantony, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2020
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple SclerosisSophie Mathais, Xavier Moisset, Bruno Pereira, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Radiation Research|December 4, 2003
Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrastLois B Travis, Michael Hauptmann, Linda Knudson Gaul, et al.
Plos One|July 7, 2015
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational StudyEmmanuelle Leray, Sandra Vukusic, Marc Debouverie, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2020
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MSMikael Cohen, Lydiane Mondot, Florence Bucciarelli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2024
Association between education level and disability progression in patients with multiple sclerosis in FranceMathilde Lefort, Olivier Dejardin, Eric Berger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in FranceMathilde Lefort, Olivier Dejardin, Eric Berger, et al.
Annals of Clinical and Translational Neurology|August 8, 2025
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple SclerosisAlexandra Garcia, Stephane Rodriguez, Emilie Dugast, et al.
Annals of Clinical and Translational Neurology|April 8, 2021
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament-light chain in multiple sclerosisAudrey Gauthier, Sébastien Viel, Magali Perret, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 22, 2023
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple SclerosisAlexandra Garcia, Emilie Dugast, Sita Shah, et al.
Neurology|October 12, 2023
Comparison of 2 Methods for Estimating Multiple Sclerosis-Related MortalityFabien Rollot, Zoé Uhry, Emmanuelle Dantony, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2020
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple SclerosisSophie Mathais, Xavier Moisset, Bruno Pereira, et al.
Pageof 13